Division of Hematology/Onocology and Department of Medicine and Cancer Center, Tufts Medical Center, Boston, MA, USA.
Ther Adv Med Oncol. 2013 Jan;5(1):81-9. doi: 10.1177/1758834012462463.
Pancreatic cancer is a lethal disease and remains one of the most resistant cancers to traditional therapies. Historically, chemotherapy or radiotherapy did not provide meaningful survival benefit in advanced pancreatic cancer. Gemcitabine and recently FOLFIRINOX (5-flourouracil, leucovorin, oxaliplatin and irinotecan) have provided some limited survival advantage in advanced pancreatic cancer. Targeted agents in combination with gemcitabine had not shown significant improvement in the survival. Current therapies for pancreatic cancer have their limitations; thus, we are in dire need of newer treatment options. Immunotherapy in pancreatic cancer works by recruiting and activating T cells that recognize tumor-specific antigens which is a different mechanism compared with chemotherapy and radiotherapy. Preclinical models have shown that immunotherapy and targeted therapies like vascular endothelial growth factor and epidermal growth factor inhibitors work synergistically. Hence, new immunotherapy and targeted therapies represent a viable option for pancreatic cancer. In this article, we review the vaccine therapy for pancreatic cancer.
胰腺癌是一种致命的疾病，仍然是对传统疗法最具抵抗力的癌症之一。历史上，化疗或放疗并没有为晚期胰腺癌提供有意义的生存获益。吉西他滨和最近的 FOLFIRINOX（5-氟尿嘧啶、亚叶酸钙、奥沙利铂和伊立替康）在晚期胰腺癌中提供了一些有限的生存优势。吉西他滨联合靶向药物在生存方面没有显著改善。目前胰腺癌的治疗方法存在局限性；因此，我们迫切需要新的治疗选择。胰腺癌的免疫疗法通过招募和激活识别肿瘤特异性抗原的 T 细胞起作用，这与化疗和放疗的机制不同。临床前模型表明，免疫疗法和靶向疗法（如血管内皮生长因子和表皮生长因子抑制剂）具有协同作用。因此，新的免疫疗法和靶向疗法为胰腺癌提供了一种可行的选择。在本文中，我们综述了胰腺癌的疫苗治疗。
